No Data
Chengdu Olin Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Gelonghui Announcement Highlights: PetroChina: Net income in the third quarter was 43.911 billion yuan, a decrease of 5.3% year-on-year; Muyuan Foods: Net income in the first three quarters was 10.481 billion yuan, an increase of 668.90% year-on-year.
【Performance Report】Petrochina (601857.SH): The net income in the third quarter was 43.911 billion yuan, a decrease of 5.3% year-on-year. CNSIG Inner Mongolia Chemical Industry (600328.SH): The net income in the first three quarters was 0.574 billion yuan, a decrease of 31.72% year-on-year. Datang International Power Generation (601991.SH): The net income in the first three quarters was 4.429 billion yuan, an increase of 56.22% year-on-year. Hisense Visual Technology (600060.SH): The net income in the first three quarters was 1.31 billion yuan, a decrease of 19.53% year-on-year. Yunnan Baiyao Group (000538.SZ): The net income in the first three quarters was 4.327 billion yuan, an increase.
Olin Biology (688319.SH): The proposed additional fundraising will not exceed 0.3 billion yuan.
Great Wisdom News on October 29th: Olin Biology (688319.SH) announced that the total amount of funds raised by the company in this stock issuance shall not exceed 175.2929 million yuan (including this amount), not exceeding 0.3 billion yuan and not exceeding 20% of the net assets at the end of the latest year. The net proceeds of the funds raised after deducting the relevant issuance expenses are intended to be invested in the following project: Vaccine research and production base technology renovation project.
Olin Biology (688319.SH): The net income in the first three quarters was 4.0259 million yuan, a year-on-year decrease of 86.71%.
On October 29th, Olin Biology (688319.SH) released the third quarter report for 2024, with a company's revenue of 0.387 billion yuan for the first three quarters, a year-on-year increase of 9.75%; net income attributable to shareholders of the listed company was 4.0259 million yuan, a year-on-year decrease of 86.71%; basic earnings per share was 0.0099 yuan.
Olin Biology (688319.SH): Trivalent influenza virus split lytic vaccine (MDCK cells) has obtained the drug clinical trial approval notification.
On October 21, Olin biotechnology (688319.SH) announced that it has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration regarding the trivalent influenza virus split vaccine (MDCK cells). After receiving the influenza vaccine, it can stimulate the body to produce immunity against influenza viruses, used to prevent epidemic influenza caused by vaccine-related types of influenza viruses. Based on the vaccine components and the types of viruses prevented, the influenza vaccines currently available in China include trivalent influenza vaccines and quadrivalent influenza vaccines, with trivalent influenza vaccines mainly preventing H1N1 and H3N2 in influenza A.
Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) Business Is Trailing The Industry But Its Shares Aren't
Declining Stock and Decent Financials: Is The Market Wrong About Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319)?No Data
No Data
